403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Regeneration Biomedical, Inc. To Present First-In-Human Direct-To-Brain Autologous Stem Cell Therapy Data At CTAD 2025
(MENAFN- EIN Presswire) EINPresswire/ -- Regeneration Biomedical, Inc. (RBI) announced that it will present Phase 1 clinical results of the world's first direct-to-brain autologous stem cell therapy for Alzheimer's disease today at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.
RBI's treatment involves injecting a patient's own Wnt-expressing stem cells directly into the brain's ventricles-an FDA-cleared, first-in-human neurosurgical delivery method designed to stimulate dormant endogenous neural stem cell populations.
Following review of the Phase 1 findings, the FDA has granted clearance for RBI to advance to Phase 2, a 110-patient, five-center U.S. clinical trial.
“CTAD is where major therapeutic directions are shaped, especially as multiple conventional drug approaches continue to fall short,” said Christopher Duma, MD, FACS, Founder of RBI.“Our regenerative strategy aims not just to slow decline but to potentially activate intrinsic repair pathways in the brain.”
Recent failures-including Johnson & Johnson's AUTONOMY anti-tau program and Novo Nordisk's GLP-1 Alzheimer's study, along with the limitations of amyloid-targeting drugs Kisunla and Leqembi-underscore the need for new mechanistic approaches.
“With this FDA clearance, RBI advances into Phase 2 and moves closer to establishing a new therapeutic category for Alzheimer's and other neurodegenerative diseases,” said Bill Miller, CEO.“We are actively engaging with strategic investors to support Phase 2 execution and expansion into ALS, MS, Parkinson's disease, CTE, and stroke.”
Media Contact
Robert Lynn, COO
... | 877-240-1660
Investor Contact
Bill Miller, CEO
... | 877-240-1660
RBI's treatment involves injecting a patient's own Wnt-expressing stem cells directly into the brain's ventricles-an FDA-cleared, first-in-human neurosurgical delivery method designed to stimulate dormant endogenous neural stem cell populations.
Following review of the Phase 1 findings, the FDA has granted clearance for RBI to advance to Phase 2, a 110-patient, five-center U.S. clinical trial.
“CTAD is where major therapeutic directions are shaped, especially as multiple conventional drug approaches continue to fall short,” said Christopher Duma, MD, FACS, Founder of RBI.“Our regenerative strategy aims not just to slow decline but to potentially activate intrinsic repair pathways in the brain.”
Recent failures-including Johnson & Johnson's AUTONOMY anti-tau program and Novo Nordisk's GLP-1 Alzheimer's study, along with the limitations of amyloid-targeting drugs Kisunla and Leqembi-underscore the need for new mechanistic approaches.
“With this FDA clearance, RBI advances into Phase 2 and moves closer to establishing a new therapeutic category for Alzheimer's and other neurodegenerative diseases,” said Bill Miller, CEO.“We are actively engaging with strategic investors to support Phase 2 execution and expansion into ALS, MS, Parkinson's disease, CTE, and stroke.”
Media Contact
Robert Lynn, COO
... | 877-240-1660
Investor Contact
Bill Miller, CEO
... | 877-240-1660
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment